Participated · Series A · Jul 2026

Wellumio develops a portable neuroimaging platform called Axana that uses patented PGFM (pulsed gradient–free mapping) technology to deliver rapid MRI-based stroke assessments at the point of care. The technology is designed to operate without contrast agents, cryogenics, or shielded rooms, enabling use in critical care settings. The company completed initial human feasibility trials and received a U.S. patent for its technology in December 2025. Wellumio is progressing toward regulatory approval and plans expanded clinical evaluation across additional sites and geographies. The company is led by co-founder and CEO Dr. Shieak Tzeng and is based in Wellington, New Zealand.